Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Intangibles (2020 - 2025)

Historic Intangibles for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $44000.0.

  • Burning Rock Biotech's Intangibles fell 4133.33% to $44000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $44000.0, marking a year-over-year decrease of 4133.33%. This contributed to the annual value of $58000.0 for FY2024, which is 5735.29% down from last year.
  • As of Q3 2025, Burning Rock Biotech's Intangibles stood at $44000.0, which was down 4133.33% from $49000.0 recorded in Q2 2025.
  • Over the past 5 years, Burning Rock Biotech's Intangibles peaked at $756000.0 during Q2 2021, and registered a low of $44000.0 during Q3 2025.
  • For the 5-year period, Burning Rock Biotech's Intangibles averaged around $295526.3, with its median value being $175000.0 (2023).
  • As far as peak fluctuations go, Burning Rock Biotech's Intangibles soared by 212352.94% in 2021, and later crashed by 6680.0% in 2023.
  • Quarter analysis of 5 years shows Burning Rock Biotech's Intangibles stood at $633000.0 in 2021, then plummeted by 54.5% to $288000.0 in 2022, then crashed by 52.78% to $136000.0 in 2023, then plummeted by 57.35% to $58000.0 in 2024, then decreased by 24.14% to $44000.0 in 2025.
  • Its Intangibles stands at $44000.0 for Q3 2025, versus $49000.0 for Q2 2025 and $53000.0 for Q1 2025.